New IP legislation will encourage medical research in Australia, says trade group

20 March 2012

New legislation overhauling the Australian patent system will encourage medical research and bring Australia into line with intellectual property systems in other OECD countries, says Medicines Australia chief executive Brendan Shaw.

The Raising the Bar Bill, which was finally passed in Federal Parliament on Monday night (March 19), introduces a “research use exemption” which will allow scientists to conduct research on patented inventions without infringing those patents. The bill was passed by the Senate on February 27.

“This Bill makes it absolutely clear that scientists are free to conduct research on patented inventions, so long as the purpose of that research is investigation and not the infringement of valid patents,” Dr Shaw said, adding: “It serves to allay concerns that patents can potentially stifle scientific research.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology